Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group

Overview of attention for article published in BMC Cancer, March 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (79th percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

So far, Altmetric has seen 23 X posts from 20 X users, with an upper bound of 55,481 followers.

RT @BibliotecaHUCA: PubMed-https://t.co/KXSYF2jjiI Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patient…

RT @bmassutis: 👇Con la participación de Oncologia Mèdica @GVAsalualicante @isabial_iis

RT @gecp_org: 🔊BMC Cancer publica datos del estudio OSIREX del GECP👉 estudio retrospectivo, multicéntrico y observacional que confirma cost…

RT @BoschBarrera: Un placer colaborar en este estudio multicéntrico liderado por el @gecp_org @ICOnoticies @htrueta. Es importante que disp…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 19 additional X posts.